OsteoVive®
Viable Cell Allograft
An advanced allograft solution containing all three necessary components for bone regeneration
1. McLain,R.F.,etal.,Aspirationofosteoprogenitorcellsforaugmentingspinalfusion.JournalofBoneand JointSurgery,2005.87-A(12):p.2655-2661.2. Gruskin,E.et.al.Demineralizedbonematrixinbonerepair:historyanduse.AdvancedDrugDelivery Reviews.2012;64:1063-1077.3. Dataonfile
OsteoViveisatrademarkofBacterinInternational,asubsidiaryofXtantMedical©XtantMedical.AllRightsReserved.FM-C-MRK-74(C)4/20
888.886.9354 [email protected] xtantmedical.com
OsteoVive®
Viable Cell Allograft
OsteoViveviablecellallograftprovidesbothanosteoconductivescaffoldandosteoinductivepotentialwithoutsacrificingtheviabilityofitscellularelement.Afterprocessing,whatremainsisaviablecellpopulationforosteogenicsupplementationasaviablestructuralallograft.Thesebonederivedcellsincombinationwiththebonescaffold,provideabasisfortissuesupplementationthatcarriestheintentionsofautograftwithoutthecomplicationsrelatedtoitsharvest.
Item# ProductName
203101 OsteoVive1.0cc
203102 OsteoVive2.5cc
203105 OsteoVive5.0cc
203110 OsteoVive10.0cc
Osteogenic potential–reliablecellpopulation derivedfromthevertebralbodyregion,anarea knowntoberichinMSCs¹
Osteoinductive potential–demineralizedbone componentcontainsinherentgrowthfactorsthat aidincelldifferentiation²
Osteoconductive–three-dimensionalscaffold providesincreasedsurfaceareaforoptimalcell attachment
Novel cryoprotectant -cellviabilityandfunction ispreservedusingaDMSO-freecryoprotectant thatdoesnotrequiredecantingpriortouse
Safe & non-immunogenic-processedinanaseptic mannerusingproprietaryproceduresandrigorous screeningcriteriathatexceedFDAandAATBguidelines
2 years shelf life when stored at -65° C or colder
Product qualification testing helps assure a consistent, highly active
bone regenerative cell population.
Average Cell viability post-thaw3
90% ————————––––––––––––––––––––––
80% ————————––––––––––––––––––––––
70% ————————––––––––––––––––––––––
60% ————————––––––––––––––––––––––
50% ————————––––––––––––––––––––––
OsteoVive contains a minimum of 150,000 viable cells per cc of allograft post-thaw.
OsteoVive
Via
bilit
y Pe
rcen
tage
(%)
Industry Average
Top Related